ClinicalTrials.Veeva

Menu

MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application

U

University of Ulm

Status and phase

Completed
Phase 2

Conditions

Contrast Media Exposition
Chronic Renal Insufficiency
Serum Creatinine Concentration

Treatments

Drug: sodium 2-mercaptoethane sulfonate

Study type

Interventional

Funder types

Other

Identifiers

NCT00223548
A119/2002

Details and patient eligibility

About

The purpose of this study is to determine wether Mesna could prevent contrast-induced nephropathy

Full description

Contrast-induced nephropathy remains a common complication of radiographic precedures. Pretreatment with Mesna (Sodium 2-mercaptoethane sulfonate) in combination with sodium chloride is more protective than sodium chloride alone in animal models of acute renal failure.

The aim of this study is therefore to determine laboratory and clinical benefit of MESNA, as an adjunct to saline hydration, in patients with known renal impairment receiving contrast media.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • stable chronic renal insufficiency
  • serum creatinine concentration > 1,5 mg/dl

Exclusion criteria

  • Dialyzed patients
  • patients with acute renal failure
  • received iodinated contrast media within 7 days before study entry
  • known allery to Mesna, pregnancy, and administration of dopamine, mannitol or N-acetylcysteine

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems